Jason M. Glanz, PhD
Senior Investigator
Jason M. Glanz, PhD, is a Senior Investigator at the Institute for Health Research. Dr. Glanz's research focuses on vaccine safety, vaccine acceptance, substance abuse, and epidemiological methods.
Dr. Glanz earned his Master of Science degree in biostatistics from the University of Massachusetts Amherst and completed his doctoral training in epidemiology at the Colorado School of Public Health. He is a co-principal investigator for the Vaccine Safety Datalink (VSD), a nationwide Centers for Disease Control and Prevention-funded project that examines the safety of vaccines and leads research efforts to develop risk communication tools to reduce parental vaccination concerns. He also conducts observational studies to assess the risks of opioid use and interventions to minimize overdose risk.
Dr. Glanz is an Associate Clinical Professor of Epidemiology in the Department of Epidemiology at the University of Colorado School of Public Health.
Selected Research:
- Vaccine Safety Datalink Project
- Funder: Centers for Disease Control & Prevention
- Award End Date: 09/27/2027
- Vaccine Safety Datalink Project, VSD COVID-19 Infrastructure and participating activities
- Funder: Centers for Disease Control & Prevention
- Award End Date: 01/06/2026
- Population-Level Assessment of Early Childhood Vaccination Timeliness, Parental Vaccine Hesitancy, and Immunization Schedule Adherence in the United States, Including Rural-Urban Disparities
- Funder: National Institutes of Health
- Award End Date: 08/31/2025
- Health Insurance Instability and Mortality Among Patients Receiving Buprenorphine Treatment for Opioid Use Disorder: Linkage of the Prescription Opioid Registry With the National Death Index
- Funder: National Institutes of Health/National Institute on Drug Abuse
- Award End Date: 02/28/2023
- Assessing the Safety and Effectiveness of Opioid Tapering in Large Health Systems.
- Funder: National Institute on Drug Abuse
- Award End Date: 12/31/2022
- The Safety and Impact of Expanded Access to Naloxone in Health Systems
- Funder: National Institute on Drug Abuse
- Award End Date: 04/30/2021
The goal of this project is to evaluate the safety of currently licensed (or authorized for emergency use) vaccines in the United States. To accomplish this, we lead specific vaccine safety studies, and use privacy-protecting approaches to contribute electronic health record data to multiple vaccine safety investigations.
The goal of this project is to conduct safety surveillance monitoring of COVID-19 vaccines across 8 integrated health care sites of the Vaccine Safety Datalink.
Use annual National Immunization Survey-Child (NIS-Child) data to examine patterns and trends of childhood vaccination patterns across the US and determine whether trends in schedule adherence or impact on completion of vaccine series are modified by rurality.
The purpose of this study is to examine the association of insurance instability (i.e., duration and frequency of disenrollment and transitions in plan types) and mortality risk among patients receiving buprenorphine treatment for opioid use disorder.
This study will use epidemiological methods to examine the safety and effectiveness of opioid prescribing practices across three large health systems.
Our study will examine the impact and safety of expanded access to naloxone, an effective opioid antidote which reverses opioid overdose, for patients prescribed opioids for pain in two large and diverse health systems.